Evaluating doxycycline for treating Thyroid Associated Ophthalmopathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of doxycycline in treating Thyroid Associated Ophthalmopathy (TAO) using multi-modal imaging techniques. TAO is an autoimmune condition that leads to the enlargement of extraocular muscles and increased orbital fat, affecting visual function and appearance. The study aims to provide more accurate measurements of treatment outcomes compared to traditional subjective methods. Participants will be monitored for changes in symptoms and imaging results over the course of the treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Informed consent
* Age 18-70 years old
* Diagnosed with TAO

Exclusion Criteria:

* Sight-threatening TAO with dysthyroid optic neuropathy
* Allergy of tetracycline
* Have contraindications of MRI(metal pacemaker, fake teeth, foreign body and other materials which will disturb the examination)

Where it's running

• Zhongshan Ophthalmic Center
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Dan Liang — Zhongshan Ophthalmic Center, Sun Yat-sen University
• Study coordinator: Dan Liang
• Email: liangdan@gzzoc.com
• Phone: （86）-87330402

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Precise diagnosis and treatment system for thyroid-associated eye disease

  This project will test whether a deep-learning system using eye images and exams can automatically diagnose, stage, and help plan treatment for people with thyroid-associated ophthalmopathy.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07124572

• Combining Tocilizumab and Flupentixol-Melitracen for Thyroid Eye Disease Treatment

  This study is testing if combining two medications, Tocilizumab and Flupentixol-Melitracen, can help people with thyroid eye disease feel better and improve their eye symptoms.

  Recruiting Phase 4 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT06927375

• Multiparametric prediction models for moderate to severe thyroid-associated eye disease

  This project will try to build and test combined imaging and lab-marker models to predict outcomes in adults with moderate to severe thyroid-associated ophthalmopathy.

  Recruiting Shanghai Changzheng Hospital · Shanghai, Shanghai Municipality · NCT06590220

• Comparing short and standard radiation therapy for thyroid eye disease

  This study is testing if fewer sessions of radiation therapy can help people with moderate to severe thyroid eye disease just as well as the standard number of sessions, while also making their experience better.

  Recruiting Phase 3 Mahidol University · Bangkok Noi · NCT06392906

• Evaluating linsitinib for thyroid eye disease

  This study is testing if a new drug called linsitinib can help people with moderate to severe thyroid eye disease who haven't improved with other treatments.

  Recruiting at 2 sites Phase 2/3 Sling Therapeutics, Inc. · Miami, Florida and 1 other locations · NCT06112340

• Comparing Sirolimus and Corticosteroids for Thyroid Eye Disease

  This study tests whether Sirolimus can be a safer and more effective treatment for people with moderate-to-severe thyroid eye disease compared to traditional corticosteroids.

  Recruiting Phase 2 Haukeland University Hospital · Bergen, Hordaland · NCT04936854

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.